CD80-transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens

Blood

Volumn 92, Issue 5, 1998, Pages 1677-1684

  Mutis, Tuna ^a   Schrama, Ellen ^a   Melief, Cornelis J M ^a   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LEUKEMIA ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS CELL TRANSFORMATION;

EID: 0032170977     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1677.417k14_1677_1684     Document Type: Article

References (39)

1. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068, 1979
2. Bortin MM, Truitt RL, Rimm AA, Bach FH: Gruft versus leukemia reactivity induced by alloimmunization without augmentation of graft versus host reactivity. Nature 281:490, 1979
3. Weiden PL, Fluorooy N, Sanders JE, Sullivan KM, Thomas ED: Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic bone marrow transplantation. Transplant Proc 13:248, 1981
4. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Bagder C, Beatty P, Besinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill' R, Laughran T, Martin P, Neiman P, Peterson FB, Sanders J, Singer J, Stewart P, Thomas ED: Influence of acute and chronic graft versus host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720, 1989
5. Truitt RL, Shin CY, Lelevre AV, Tempelis LD, Andreani M, Bortin MM: Characterisation of alloimmunisation-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-versus-leukemia activity in vivo. J Immunol 131:2050, 1983
6. Gale RP, Champlin RE: How does bone-marrow transplantation cure leukemia. Lancet 2:28, 1984
7. Poynton CH: T cell depletion in bone marrow transplantation. Bone Marrow Transplant 3:265, 1988
8. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS. Bortin MM: T cell depletion of HLA identical transplants in leukemia. Blood 78:2120, 1991
9. Goulmy E: Human minor histocompatibility antigens: New concepts for marrow tranplantation and adoptive immunotherapy. Immunol Rev 157:125, 1997
10. Van der Harst D, Goulmy E, Falkenburg JHF, Kooij-Winkelaar YM, van Luxemburg-Heijs SA, Goselink HM, Brand A: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T cell clones. Blood 83:1060, 1994
11. Falkenburg JHF, Goselink HM van der Harst D, van Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM, de Kroon J, Brand A, Fibbe WE, Willemze R, Goulmy E: Growth inhibition of clonogenic leukemic precursor cells by histocompatibility antigen specific cytotoxic T lymphocytes. J Exp Med 174:27, 1991
12. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal and leukemic B cells through a CD40-dependent signal. J Exp Med 177:925, 1993
13. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92:8200, 1995
14. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM: Ex vivo generation of human anti-pre-B leukemia-Specific autologous cytolytic T cells. Blood 90:549, 1997
15. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome positive chronic myelogenous leukemia. Blood 89:1133, 1997
16. Bain C, Merrouche Y, Puisreux I, Duc A, Colombo MP, Favrot M: B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer 67:769, 1996
17. Gajewski TF, Fallarino F, Uyttenhove C, Boon T: Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization. J Immunol 156:2909, 1996
18. Li Y, Hellstrom KE, Newby SA, Chen L: Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 183:639, 1996
19. Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S: Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J Immunol 156:3821, 1996
20. Chaux P, Martin MS, Martin F: T-cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor. Int J Cancer 66:244, 1996
21. Fujii H, Inobe M, Kimura F, Murata J, Murakami M, Onishi Y, Azuma I, Uede T, Saiki I: Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int J Cancer 66:219, 1996
22. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619, 1995
23. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507, 1995
24. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop JM, Arceci RJ: Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87:2938, 1996
25. + early progenitor cells. Blood 90:1083, 1997
26. + cytotoxic T cell clones: A novel immunoregulatory interaction in man. J Exp Med 171:2011, 1990
27. De Koster S, Kenter MJH, D'Amaro J, Luiten RM, Schroeijers WEM, Giphart M, Termijtelen A: Positive correlation between oligo-nucleotide typing and T cell recognition of HLA-DP molecules. Immunogenetics 34:12, 1991
28. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109, 1994
29. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83, 1994
30. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-α cooperate in the generation of dendritic langerhans cells. Nature 360:258, 1992
31. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD: B7-1 is superior to B7-2 costimulation in the induction and maintenance of T-cell mediated anti-leukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 156:1126, 1996
32. Lu P, Wang LY, Linsley PS: Regulation of self tolerance by CD80/CD86 interactions Curr Opin Immunol 9:858, 1997
33. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 178:27, 1993
34. Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM: Specific recognition of human leukemic cells by allogeneic cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. Blood 75:2005, 1990
35. van Lochern E, de Gast GC, Goulmy E: In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 10:181, 1992
36. Falkenburg JHF, Faber LM, van den Elshout M, van Luxemburg-Heijs SAP, Hooftman-den Otter A, Smit WM, Voogt PL Willemze R: Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation. J Immunother 14:305, 1993
37. Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283, 1992
38. Dolstra H, Fredrix H, Preijers F, Goulmy E, Figdor CG, de Witte TM, van de Wiel-Kemenade E: Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 158:560, 1997
39. Robbins PF, Kawakami Y: Human tumor antigens recognized by T cells. Curr Opin Immunol 8:628, 1996